THE South African coronavirus variant is better at "breaking through" the defences of the Pfizer/BioNTech vaccine than other forms of the virus, Israeli experts said Sunday.
However, one of the authors told AFP that while the study showed the variant to be relatively successful in infecting vaccinated people, it did not provide any data on whether it could generate serious illness among vaccinees.
The study by Tel Aviv University and Clalit Health Services, Israel's largest healthcare provider, compared 400 unvaccinated people infected with COVID-19 to 400 partially or fully vaccinated people who also had the virus.
According to the study, published as a draft on Saturday and currently being peer reviewed, the South African variant accounted for less than one percent of coronavirus cases in Israel.
But, among the 150 people in the study who were fully vaccinated and had COVID-19, "the prevalence rate (of the South African variant) was eight times higher than the rate in the unvaccinated (individuals)," the study said.
"This means that the Pfizer-BioNtech vaccine, though highly protective, probably does not provide the same level of protection against the South African (B.1.351) variant of the coronavirus," the study added.
"The South African variant is able, to some extent, to break through the vaccine's protection," said professor Adi Stern of Tel Aviv University's Shmunis School of Biomedicine and Cancer Research, one of the study's authors.
Stern told AFP Sunday the study did not assess whether the fully vaccinated Israelis with the South African variant eight people in total developed serious illness.
"Since we found a very small number of vaccinees infected with B.1.351, it is statistically meaningless to report disease outcomes," he said.
- Preventative measures -
Two studies published in February in the New England Journal of Medicine conducted by principal vaccine manufacturers Pfizer/BioNTech and Moderna showed that the presence of antibodies after vaccination was less pronounced in people exposed to the South African variant, indicating diminished protection.
The Israeli study was the first real-world assessment of the South African variant's ability to bypass a vaccine.
Israel's vaccination campaign has seen 5.3 million people receive a first dose, while 4.9 million, or 53 percent of the population, have had two shots.
An earlier study by Clalit on 1.2 million Israelis found that the Pfizer/BioNTech jab gave 94 percent protection against COVID-19.
Following the successful vaccination rollout, Israel has eased many of its restrictions but various measures remain in place including mask-wearing and a "green passport" system that grants access to certain sites only to those vaccinated.
Ran Balicer of Clalit, one of the study's authors, told AFP the results could help inform states on how best to ease restrictions.
Balicer said inoculations, plus mask-wearing and other safety measures had still likely helped limit the spread of the South African variant, despite its apparent ability to break through the Pfizer/BioNTech vaccine.
A combination of all these factors "are most likely... preventing the virus strains, including the South African one, from spreading" significantly in Israel, he said.
"As we taper down the non-pharmaceutical interventions, we must do so gradually to ensure we do not cross a threshold that would enable these variants to spread."
Reuters
Tue Apr 13 2021
![S. African COVID-19 variant better at bypassing Pfizer/BioNTech jab - Study S. African COVID-19 variant better at bypassing Pfizer/BioNTech jab - Study](https://resizer-awani.eco.astro.com.my/tr:w-177,h-100,q-100,f-auto/https://img.astroawani.com/2021-01/81611702699_TBNURSEHUNGARYVACC.jpg)
The South African variant is able, to some extent, to break through the vaccine's protection. - AP NEWSROOM
10 Berita Pilihan - (16 Julai 2024
Antara pelbagai berita dalam dan luar negara yang disiarkan di Astro AWANI, berikut adalah yang paling menjadi tumpuan sepanjang hari ini.
PAC beri tempoh tiga bulan kepada HRD Corp
Jawatankuasa Kira-kira Wang Negara (PAC) memberi tempoh tiga bulan kepada Perbadanan Pembangunan Sumber Manusia (HRD Corp) untuk mengemukakan laporan tindakan susulan terhadap syor jawatankuasa itu.
Kylian Mbappe tandatangan kontrak dengan Real Madrid
Bintang bola sepak Perancis Kylian Mbappe menandatangani kontrak selama lima tahun dengan kelab Sepanyol Real Madrid pada Selasa.
Pelepasan ketujuh air sisa nuklear Fukushima ke laut selesai
Jepun telah menyelesaikan pusingan ketujuh pelepasan air sisa radioaktif yang dirawat dari loji kuasa nuklear Fukushima Daiichi ke Lautan Pasifik pada Selasa.
Empat termasuk kapten maut dalam pertempuran
Empat anggota tentera India termasuk kapten meninggal dunia akibat kecederaan selepas pertempuuran pada malam isnin di Hutan Desa.
Pakistan sahkan 4 warganya terbunuh di Oman
Pakistan berkata pada Selasa empat warganya terbunuh dalam insiden tembakan pada malam Isnin berhampiran ibu negara Oman, Muscat.
Lima terbunuh, puluhan cedera dalam protes antikuota di Bangladesh
Sekurang-kurangnya empat orang terbunuh dan puluhan lagi cedera dalam pertempuran antara pelajar yang memprotes sistem kuota dalam pekerjaan sektor awam dan polis di pelbagai bahagian Bangladesh pada Selasa.
Kerajaan cadang perkenal pembiayaan swasta
Kerajaan menyasarkan untuk memperkenalkan pembiayaan swasta alternatif bagi memastikan kemampanan kewangan program sektor air, sekali gus mengurangkan kebergantungan pada perbelanjaan kerajaan dan mengukuhkan daya tahan.
Saya tak fitnah Guan Eng, cuma jelaskan siasatan SPRM - Muhyiddin
Presiden Bersatu Tan Sri Muhyiddin Yassin memberitahu Mahkamah Tinggi Kuala Lumpur hari ini bahawa beliau tidak memfitnah Lim Guan Eng berhubung isu pengecualian cukai terhadap Yayasan Albukhary
KPT alu-alukan dapatan, cadangan PAC - Zambry
Ini termasuklah cadangan pelaksanaan Garis Panduan Pelaburan dan Pembiayaan oleh Universiti Awam 2024 kepada anak-anak syarikat di bawah seliaan Kementerian Pendidikan Tinggi (KPT).
![Vaksin COVID-19: FDA lulus penuh Pfizer untuk usia 12-15 tahun Vaksin COVID-19: FDA lulus penuh Pfizer untuk usia 12-15 tahun](https://resizer-awani.eco.astro.com.my/tr:w-177,h-100,q-100,f-auto/https://img.astroawani.com/2022-06/61654223659_TBVACCINE.jpg)
Vaksin COVID-19: FDA lulus penuh Pfizer untuk usia 12-15 tahun
Vaksin itu sebelum ini mendapat kelulusan kecemasan bagi kumpulan umur berkenaan sejak Mei 2021.
![Vaksin COVID-19: Kanak-kanak bawah lima tahun terima suntikan Vaksin COVID-19: Kanak-kanak bawah lima tahun terima suntikan](https://resizer-awani.eco.astro.com.my/tr:w-177,h-100,q-100,f-auto/https://img.astroawani.com/2022-06/81655771240_VialswithPfizerBi.jpg)
Vaksin COVID-19: Kanak-kanak bawah lima tahun terima suntikan
Rata-rata menyambut baik keputusan tersebut dengan ibu-bapa membawa anak-anak mereka mendapatkan vaksinasi.
![Vaksin COVID-19: AS mula suntik kanak-kanak bawah 5 tahun 21 Jun ini Vaksin COVID-19: AS mula suntik kanak-kanak bawah 5 tahun 21 Jun ini](https://resizer-awani.eco.astro.com.my/tr:w-177,h-100,q-100,f-auto/https://img.astroawani.com/2022-06/61654223659_TBVACCINE.jpg)
Vaksin COVID-19: AS mula suntik kanak-kanak bawah 5 tahun 21 Jun ini
Kerajaan persekutuan akan menyediakan 10 juta vaksin kepada pihak berkuasa negeri dan tempatan untuk memulakan vaksinasi meluas.
![Vaksin COVID-19: Pfizer didapati selamat untuk kanak-kanak bawah 5 tahun Vaksin COVID-19: Pfizer didapati selamat untuk kanak-kanak bawah 5 tahun](https://resizer-awani.eco.astro.com.my/tr:w-177,h-100,q-100,f-auto/https://img.astroawani.com/2022-04/61649990609_pfizer.jpg)
Vaksin COVID-19: Pfizer didapati selamat untuk kanak-kanak bawah 5 tahun
Berdasarkan ujian klinikal terbaharu, keberkesanan vaksin bagi tiga dos adalah pada kadar 80.3 peratus.
![COVID-19 : Vaksin mRNA China sasar Omicron jalani ujian di UAE COVID-19 : Vaksin mRNA China sasar Omicron jalani ujian di UAE](https://resizer-awani.eco.astro.com.my/tr:w-177,h-100,q-100,f-auto/https://img.astroawani.com/2022-02/61644549072_OMICRON.jpg)
COVID-19 : Vaksin mRNA China sasar Omicron jalani ujian di UAE
Syarikat Suzhou Abogen Biosciences Co Ltd menyertai Pfizer-BioNTech dan Moderna dalam menguji calon vaksin yang diubah suai secara khusus menentang Omicron.
![Vaksin COVID-19: Dos penggalak tingkat perlindungan terhadap Omicron - Pfizer Vaksin COVID-19: Dos penggalak tingkat perlindungan terhadap Omicron - Pfizer](https://resizer-awani.eco.astro.com.my/tr:w-177,h-100,q-100,f-auto/https://img.astroawani.com/2022-01/41642464886_Indigenouschild.jpg)
Vaksin COVID-19: Dos penggalak tingkat perlindungan terhadap Omicron - Pfizer
Analisis serum darah 30 kanak-kanak yang menerima dos penggalak menunjukkan peningkatan 36 kali ganda dalam antibodi peneutral Omicron.
![Pfizer, BioNTech mohon kebenaran FDA untuk dos penggalak kedua Pfizer, BioNTech mohon kebenaran FDA untuk dos penggalak kedua](https://resizer-awani.eco.astro.com.my/tr:w-177,h-100,q-100,f-auto/https://img.astroawani.com/2021-03/81616716267_vaccine.jpg)
Pfizer, BioNTech mohon kebenaran FDA untuk dos penggalak kedua
FDA berkata ia akan menyemak permintaan Pfizer dan BioNTech "secepat mungkin menggunakan pendekatan menyeluruh dan berasaskan sains."
![Ibu bapa perlu sasarkan kerisauan kepada jangkitan COVID-19, bukan vaksin Ibu bapa perlu sasarkan kerisauan kepada jangkitan COVID-19, bukan vaksin](https://resizer-awani.eco.astro.com.my/tr:w-177,h-100,q-100,f-auto/https://img.astroawani.com/2022-02/41644382172_PICKids.jpg)
Ibu bapa perlu sasarkan kerisauan kepada jangkitan COVID-19, bukan vaksin
Rata-rata ibu bapa memberi alasan tidak mahu anak mereka diperlakukan seperti "tikus makmal".
![PICKids Pahang bermula Isnin PICKids Pahang bermula Isnin](https://resizer-awani.eco.astro.com.my/tr:w-177,h-100,q-100,f-auto/https://img.astroawani.com/2022-02/41643903009_TBUGGAHPICKIDS.jpg)
PICKids Pahang bermula Isnin
Buat permulaan hanya satu jenis vaksin sahaja yang ditawarkan iaitu Corminaty (Pfizer-BioNTech) dos kanak-kanak.
![PICKids: 517,107 kanak-kanak daftar terima vaksin setakat 1 Feb - Khairy PICKids: 517,107 kanak-kanak daftar terima vaksin setakat 1 Feb - Khairy](https://resizer-awani.eco.astro.com.my/tr:w-177,h-100,q-100,f-auto/https://img.astroawani.com/2022-01/81643299190_KhairyJamaluddin.jpg)
PICKids: 517,107 kanak-kanak daftar terima vaksin setakat 1 Feb - Khairy
Selangor mencatatkan pendaftaran paling tinggi iaitu lebih 131,000 orang, diikuti Johor (81,400) dan Wilayah Persekutuan Kuala Lumpur.